<DOC>
	<DOCNO>NCT00147238</DOCNO>
	<brief_summary>The goal clinical research study evaluate well ferumoxtran-10 , new Magnetic Resonance Imaging ( MRI ) contrast agent , detect cancer pelvic lymph node malignant pelvic lymph node .</brief_summary>
	<brief_title>A Validation Study MR Lymphangiography Using SPIO , New Lymphotropic Superparamagnetic Nanoparticle Contrast</brief_title>
	<detailed_description>The contrast agent , ferumoxtran-10 , make ultra small iron oxide particle ( USPIO ) . Once injected vein , take mostly liver , spleen , bone marrow , lymph node . It take 24 - 36 hour reach peak uptake lymph node . The ability current image technique detect lymph node disease know less perfect . Current technique use anatomic information ( size ) . Previous study show new contrast agent may able detect normal abnormal lymph node , use MRI procedure , call MRI lymphangiogram . This new contrast agent evaluate determine whether use detect normal abnormal lymph node . The study include 2 part . The first part involve receive MRI examination contrast inject . The second part involve receive MRI examination 24 hour injection . It take 20 minute part . If already schedule routine pelvic MRI , first part study add end routine MRI . You ask return next day complete second part MRI . If already schedule receive MRI part standard care , come MRI suite M. D. Anderson complete part 24-hour interval . You lie MRI examination table scanning . At end first part study , contrast infuse slowly vein 30 minute recovery area . You observe 30 minute 2 hour , depend tolerance contrast agent . The image take first part repeat 24-36 hour later . You receive follow-up telephone call member study staff Day 3 . Once second part MRI perform , participation study . This investigational study . This contrast agent currently evaluate FDA approve yet . A total 80 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urogenital Neoplasms</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>1 . Patients newly diagnose pelvic urological tumor , include prostate carcinoma , bladder carcinoma , penile carcinoma . 2 . Planned surgical exploration laparoscopy pelvic lymph node dissection/biopsy within 4 week . 3 . Signed write consent HIPAA authorization 1 . Contraindications MRI 2 . Claustrophobia , metal pelvis , previous pelvic surgery 3 . Allergy hypersensitivity iron product , dextrans , irondextran complex 4. a. Prostate cancer : metastasis demonstrate preoperative imaging ; prior hormonal therapy great 3 month ; prior local therapy prostate cancer b. Penile Cancer : prior systemic therapy penile cancer ; prior inguinal radiation c. Bladder Cancer : prior systemic therapy bladder cancer ( NOT include intravesical chemotherapy immunotherapy ) ; prior pelvic radiation ; history partial cystectomy prior pelvic lymph node dissection 5 . Women childbearing potential . ( Women hysterectomy part bladder surgery exclude . ) 6 . Clinically document risk primary secondary iron overloading ( e.g.History thalassemia , sickle cell anemia , hereditary hemochromatosis , multiple transfusion reason )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Genitourinary Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>MR Lymphangiography</keyword>
	<keyword>Ferumoxtran-10</keyword>
	<keyword>SPIO</keyword>
	<keyword>Ultra-small superparamagnetic agent iron oxide</keyword>
</DOC>